Biote Q3 revenue falls 9.6%, misses analyst expectations on soft procedure segment
BTMD•Biote's third-quarter revenue fell 9.6% year over year to $43.33 million, below the $45.07 million analyst estimate, while adjusted EPS was $0.01. The company maintained its 2026 outlook, including revenue above $175 million and adjusted EBITDA above $25 million.
1. Revenue declines
Biote reported third-quarter revenue of $43.33 million, down 9.6% year over year and below the $45.07 million consensus estimate. Procedure revenue fell 15.1%, while dietary supplements revenue rose 7.3%. Adjusted EPS was $0.01 and adjusted EBITDA was $5.10 million.
2. Outlook maintained
The company maintained its 2026 outlook, expecting revenue above $175 million and adjusted EBITDA above $25 million. It expects dietary supplements revenue to grow at a mid- to high-single-digit rate. Gross margin was 67.7%; the company said it fell due to increased use of lower-margin third-party pellets after a voluntary recall.
